Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy.

Background: Authors report clinical outcomes of patients treated with robotic stereotactic body radiotherapy (SBRT) for primary, recurrent and metastatic lung lesions.

Patients And Methods: 130 patients with 160 lesions were treated with Cyberknife SBRT, including T1-3 primary lung cancers (54%), recurrent tumors (22%) and pulmonary metastases (24%). The mean biologically equivalent dose (BED was 151 Gy (72-180 Gy).

FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.

Introduction: With (18)F-FDG PET/CT, tumor uptake intensity and heterogeneity have been associated with outcome in several cancers. This study aimed at investigating whether (18)F-FDG uptake intensity, volume or heterogeneity could predict the outcome in patients with non-small cell lung cancers (NSCLC) treated by stereotactic body radiation therapy (SBRT).

Methods: Sixty-three patients with NSCLC treated by SBRT underwent a (18)F-FDG PET/CT before treatment.

[The therapeutic potential of ablative radiotherapy for metastatic renal cell cancer: a tumour deemed radiation resistant].

Image guided Stereotactic Body Radiation Therapy (SBRT), is a valuable alternative to other ablative approaches, especially in the context of metastatic renal cell carcinoma (mRCC). The efficacy of this treatment depends on the Biological Effective Dose (BED). The BED is determined by total dose and dose per fraction.

[The CyberKnife as a perfect tool for new therapeutic challenges in radiotherapy].

The "wholy grale" in radiotherapy is the search for a treatment as conformal as possible allowing to apply very high doses on the target while leaving healthy tissues as much as possible outside the prescription isodose. Radiotherapy is characterized by a never ending technical evolution aiming at increasing biological efficacy on the target while reducing toxicity at the level of the surrounding organs at risk. One of the by-products of this ever lasting quest to precision and dose concentration is the concept of radiotherapy in stereotactic conditions.

[Pre- or postoperative adjuvant radiotherapy for soft tissue sarcomas of limbs].

Soft tissue sarcomas are rare tumours requiring a multidisciplinary approach of the diagnostic process, the treatment and the follow up. Radical surgery remains the basis of the oncological treatment. Adjuvant radiotherapy is often added to surgery because of a high risk of local recurrence for specified patient groups.

[Cyberknife and benign pathologies].

Conventional radiotherapy is known to be an effective treatment approach even for "benign" pathologies. However, this kind of treatment yields a high potential for side effects. The Cyberknife, a robotic stereotactic radiotherapy device, enables to offset a large proportion of the disadvantages encountered with conventional radiotherapy essentially through the high precision of dose administration and sparing of healthy tissues.

[I beg your pardon? I can be treated by another modality than surgery for my vestibular schwannoma].

The history of the treatment of vestibular schwannoma (VS) clearly shows a shift from microsurgery towards radiotherapy as "standard therapy". The microsurgical approach obviously yields excellent tumour control, but is hampered by a high morbidity rate, especially at the level of cranial nerves. The literature reports a normal facial nerve function in only 60% of patients surgically treated for VS with a maximum diameter of 25 mm.

[Radiotherapy in breast cancer: current standards of treatment, prediction of local recurrence and open questions].

Adjuvant radiotherapy after surgery is a ("well-established standard" in routine clinical practice for breast cancer. Nevertheless, a variety of questions still remain unanswered. We intend to illustrate the overall importance of radiotherapy in breast cancer and highlight some unresolved questions by quoting presentations recently made at ASTRO-2010.

[Image guided stereotactic treatment with CyberKnife yields surgical precision].

The field of radiation oncology is rapidly evolving especially thanks to the tremendous progress in robotics and computer sciences. One of the consequences is the implementation of a technique like the CyberKnife. This particular radiation therapy modality allows the use of "ablative" radiation doses, a concept which is not even conceivable with conventional approaches.